Alzheimer's disease.

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (2012) 10.42

The science of stroke: mechanisms in search of treatments. Neuron (2010) 6.14

Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci (2011) 5.64

Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24

Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61

Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med (2012) 3.49

Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron (2013) 3.43

Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 3.06

The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol (2014) 2.99

A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest (2012) 2.98

Repeat expansion in C9ORF72 in Alzheimer's disease. N Engl J Med (2012) 2.58

Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc Natl Acad Sci U S A (2013) 2.45

Suppression of eIF2α kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat Neurosci (2013) 2.35

The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol (2010) 2.31

Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement (2011) 2.26

The many substrates of presenilin/γ-secretase. J Alzheimers Dis (2011) 2.02

Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet (2011) 1.96

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci (2013) 1.91

Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition (2010) 1.89

Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol (2010) 1.80

Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology (2010) 1.78

Anesthetics isoflurane and desflurane differently affect mitochondrial function, learning, and memory. Ann Neurol (2012) 1.76

Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol (2015) 1.75

Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) (2010) 1.73

Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci (2012) 1.71

Atomic-resolution dynamics on the surface of amyloid-β protofibrils probed by solution NMR. Nature (2011) 1.70

Perioperative cognitive decline in the aging population. Mayo Clin Proc (2011) 1.66

Stressin' Sestrins take an aging fight. EMBO Mol Med (2010) 1.65

Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One (2011) 1.62

Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med (2015) 1.61

The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis (2010) 1.60

Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron (2013) 1.54

Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51

Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One (2010) 1.49

Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies. Kidney Int (2010) 1.47

Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. J Neurosci (2011) 1.47

Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol (2011) 1.46

Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun (2013) 1.45

Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med (2010) 1.44

Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev (2013) 1.44

Kinetics of amyloid beta monomer-to-oligomer exchange by NMR relaxation. J Am Chem Soc (2010) 1.43

Complement in the brain. Mol Immunol (2011) 1.41

Rate of early onset Alzheimer's disease: a systematic review and meta-analysis. Ann Transl Med (2015) 1.41

A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease. Mol Neurodegener (2016) 1.41

Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. PLoS One (2016) 1.40

Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer's Disease. PLoS One (2015) 1.39

Necroptosis activation in Alzheimer's disease. Nat Neurosci (2017) 1.38

Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A (2012) 1.38

Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci (2010) 1.38

CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.37

Amylin deposition in the brain: A second amyloid in Alzheimer disease? Ann Neurol (2013) 1.35

Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study. BMC Neurol (2010) 1.32

Functional screening in Drosophila identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms. Hum Mol Genet (2013) 1.32

Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.32

Human pluripotent stem cells: applications and challenges in neurological diseases. Front Physiol (2012) 1.31

Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. Curr Biol (2011) 1.31

Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol (2011) 1.30

Establishment and Dysfunction of the Blood-Brain Barrier. Cell (2015) 1.30

Alzheimer's disease: analyzing the missing heritability. PLoS One (2013) 1.28

The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol (2011) 1.27

Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One (2012) 1.25

Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J (2010) 1.24

Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J Alzheimers Dis (2010) 1.24

A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline. Hum Mol Genet (2012) 1.22

Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension. Hum Mol Genet (2012) 1.22

Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol (2013) 1.21

Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep (2013) 1.20

Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc Natl Acad Sci U S A (2011) 1.19

Insulin resistance in the nervous system. Trends Endocrinol Metab (2012) 1.18

Neurovascular function in Alzheimer's disease patients and experimental models. J Cereb Blood Flow Metab (2011) 1.18

Amyloid-Beta interaction with mitochondria. Int J Alzheimers Dis (2011) 1.18

Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci (2014) 1.18

Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene (2010) 1.17

Sevoflurane anesthesia in pregnant mice induces neurotoxicity in fetal and offspring mice. Anesthesiology (2013) 1.16

Exposure to general anesthesia and risk of Alzheimer's disease: a systematic review and meta-analysis. BMC Geriatr (2011) 1.16

Periodontitis: a potential risk factor for Alzheimer's disease. Br Dent J (2015) 1.15

Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet (2012) 1.15

Amyloid β-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J Neurosci (2011) 1.14

Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques. Cell Death Differ (2011) 1.13

Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective? J Neurosci (2011) 1.13

Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci (2015) 1.13

Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal (2012) 1.12

Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem (2011) 1.12

Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension (2012) 1.11

BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease. Mol Neurodegener (2012) 1.11

Brief review: anesthetic neurotoxicity in the elderly, cognitive dysfunction and Alzheimer's disease. Can J Anaesth (2010) 1.10

Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain (2011) 1.10

Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice. J Clin Invest (2011) 1.10

Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One (2012) 1.09

Cholinergic-associated loss of hnRNP-A/B in Alzheimer's disease impairs cortical splicing and cognitive function in mice. EMBO Mol Med (2012) 1.09

Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity. PLoS One (2012) 1.09

Functional screening of Alzheimer pathology genome-wide association signals in Drosophila. Am J Hum Genet (2011) 1.08

Pseudomonas aeruginosa exotoxin Y is a promiscuous cyclase that increases endothelial tau phosphorylation and permeability. J Biol Chem (2012) 1.08

Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord (2012) 1.08

Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta (2010) 1.07

Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease. J Alzheimers Dis (2013) 1.07

Rates of decline in Alzheimer disease decrease with age. PLoS One (2012) 1.07

Aging and sleep: physiology and pathophysiology. Semin Respir Crit Care Med (2010) 1.07

Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. Int J Clin Exp Pathol (2010) 1.07

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03

Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52

Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging (2003) 3.83

Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.18

Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A (2009) 2.96

Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80

Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci (2010) 2.79

Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56

Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci (2006) 2.45

Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33

IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol (2009) 2.16

Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12

M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron (2006) 2.07

Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci (2007) 2.00

A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97

Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci (2004) 1.92

Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci (2008) 1.88

SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol (2008) 1.84

Linking calcium to Abeta and Alzheimer's disease. Neuron (2008) 1.82

Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol (2008) 1.71

Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging (2005) 1.68

A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol (2006) 1.66

Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66

Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64

Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One (2008) 1.62

Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60

Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol (2012) 1.60

Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2007) 1.58

Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res (2008) 1.56

Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 1.55

Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem (2005) 1.52

Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium (2005) 1.52

Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51

Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.51

Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci (2008) 1.49

Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci (2007) 1.47

Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. J Neurosci (2011) 1.47

Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci (2007) 1.46

Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem (2008) 1.36

Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol (2011) 1.36

Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci (2013) 1.32

Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis (2007) 1.30

Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest (2004) 1.29

Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. Biol Psychiatry (2013) 1.28

Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry (2009) 1.25

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci (2007) 1.24

ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A (2010) 1.23

Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem (2007) 1.22

Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci (2007) 1.22

Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci (2006) 1.21

Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 1.21

Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol (2009) 1.19

Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a γ-secretase-independent manner. J Neurosci (2011) 1.18

Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS One (2010) 1.17

Ca2+ signaling in mouse cortical neurons studied by two-photon imaging and photoreleased inositol triphosphate. J Neurosci (2003) 1.17

The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris (2006) 1.11

Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A (2002) 1.11

Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J Neurosci Res (2009) 1.08

Soluble aβ promotes wild-type tau pathology in vivo. J Neurosci (2012) 1.06

Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice. Acta Neuropathol (2010) 1.05

Spatial frequency domain imaging of intrinsic optical property contrast in a mouse model of Alzheimer's disease. Ann Biomed Eng (2011) 1.05

Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res Ther (2014) 1.05

Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann N Y Acad Sci (2004) 1.03

Age-related accumulation of Reelin in amyloid-like deposits. Neurobiol Aging (2007) 1.02

Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J Biol Chem (2011) 1.01

Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol (2012) 1.01

Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res (2010) 1.00

Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis (2010) 1.00

Amyloid beta-peptide: the inside story. Curr Alzheimer Res (2004) 0.99

Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging (2005) 0.99

Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann Neurol (2011) 0.97

Presenilin regulates capacitative calcium entry dependently and independently of gamma-secretase activity. Biochem Biophys Res Commun (2004) 0.97

Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathol (2008) 0.96

Amyloid-β protein impairs Ca2+ release and contractility in skeletal muscle. Neurobiol Aging (2008) 0.94

Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol (2006) 0.93

M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res (2009) 0.93

Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. Am J Pathol (2011) 0.93

Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol (2013) 0.93

Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PLoS One (2010) 0.93

Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology. J Alzheimers Dis (2009) 0.92

Intracellular accumulation of toxic turn amyloid-β is associated with endoplasmic reticulum stress in Alzheimer's disease. Curr Alzheimer Res (2013) 0.91

The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther (2010) 0.91

Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J Neurosci (2009) 0.89

Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol Aging (2011) 0.88

APP knockout mice experience acute mortality as the result of ischemia. PLoS One (2012) 0.87

Profile for amyloid-beta and tau expression in primary cortical cultures from 3xTg-AD mice. Cell Mol Neurobiol (2009) 0.86

Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease. PLoS One (2012) 0.86

Treatment of Alzheimer's disease with anti-homocysteic acid antibody in 3xTg-AD male mice. PLoS One (2010) 0.85

Localization of cholesterol, amyloid and glia in Alzheimer's disease transgenic mouse brain tissue using time-of-flight secondary ion mass spectrometry (ToF-SIMS) and immunofluorescence imaging. Acta Neuropathol (2012) 0.85

Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol (2015) 0.84

SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Gen Physiol (2008) 0.84

Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease. Learn Mem (2012) 0.83

Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease. Age (Dordr) (2012) 0.83

Elucidating the triggers, progression, and effects of Alzheimer's disease. J Alzheimers Dis (2013) 0.82

Olfactory memory is impaired in a triple transgenic model of Alzheimer disease. Behav Brain Res (2011) 0.81

Genetic knockdown of brain-derived neurotrophic factor in 3xTg-AD mice does not alter Aβ or tau pathology. PLoS One (2012) 0.81

Amyloid deposits show complexity and intimate spatial relationship with dendrosomatic plasma membranes: an electron microscopic 3D reconstruction analysis in 3xTg-AD mice and aged canines. J Alzheimers Dis (2009) 0.81

Neuronal-specific overexpression of a mutant valosin-containing protein associated with IBMPFD promotes aberrant ubiquitin and TDP-43 accumulation and cognitive dysfunction in transgenic mice. Am J Pathol (2013) 0.79

Design and synthesis of skeletal analogues of gambierol: attenuation of amyloid-β and tau pathology with voltage-gated potassium channel and N-methyl-D-aspartate receptor implications. J Am Chem Soc (2012) 0.78